[go: up one dir, main page]

MX2010004529A - Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado. - Google Patents

Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.

Info

Publication number
MX2010004529A
MX2010004529A MX2010004529A MX2010004529A MX2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A MX 2010004529 A MX2010004529 A MX 2010004529A
Authority
MX
Mexico
Prior art keywords
combination therapy
compositions
asthma
treatment
active agent
Prior art date
Application number
MX2010004529A
Other languages
English (en)
Inventor
Roch Thibert
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MX2010004529A publication Critical patent/MX2010004529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones para inhalación que comprenden ácido montelukast y un segundo agente activo seleccionado de un inhibidor de PDE-4 y un corticoesteroide inhalado; también se proporciona un método para el tratamiento de trastornos respiratorios como asma mediante el uso de tales composiciones.
MX2010004529A 2007-10-25 2008-10-23 Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado. MX2010004529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25
PCT/CA2008/001874 WO2009052624A1 (en) 2007-10-25 2008-10-23 Combination therapy

Publications (1)

Publication Number Publication Date
MX2010004529A true MX2010004529A (es) 2010-05-10

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004529A MX2010004529A (es) 2007-10-25 2008-10-23 Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.

Country Status (19)

Country Link
US (1) US20100210611A1 (es)
EP (1) EP2211863A4 (es)
JP (1) JP2011500731A (es)
KR (1) KR20100072295A (es)
CN (1) CN101909626A (es)
AU (1) AU2008316283A1 (es)
CA (1) CA2701956A1 (es)
CO (1) CO6270213A2 (es)
CR (1) CR11439A (es)
DO (1) DOP2010000122A (es)
GT (1) GT201000107A (es)
IL (1) IL205182A0 (es)
MA (1) MA33705B1 (es)
MX (1) MX2010004529A (es)
NI (1) NI201000069A (es)
NZ (1) NZ584876A (es)
RU (1) RU2470639C2 (es)
WO (1) WO2009052624A1 (es)
ZA (1) ZA201002562B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
KR20040044946A (ko) * 2001-09-19 2004-05-31 알타나 파마 아게 Ｐｄｅ 억제제와 류코트리엔 수용체 길항제의 병용
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US7553853B2 (en) * 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
RU2437658C2 (ru) * 2004-02-06 2011-12-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
CN101175480A (zh) * 2005-03-16 2008-05-07 伊兰制药国际有限公司 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
CA2623882A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose

Also Published As

Publication number Publication date
RU2470639C2 (ru) 2012-12-27
CN101909626A (zh) 2010-12-08
CR11439A (es) 2010-06-21
AU2008316283A1 (en) 2009-04-30
US20100210611A1 (en) 2010-08-19
MA33705B1 (fr) 2012-11-01
ZA201002562B (en) 2011-06-29
WO2009052624A9 (en) 2010-11-25
RU2010120806A (ru) 2011-11-27
JP2011500731A (ja) 2011-01-06
WO2009052624A1 (en) 2009-04-30
CO6270213A2 (es) 2011-04-20
DOP2010000122A (es) 2010-07-15
KR20100072295A (ko) 2010-06-30
IL205182A0 (en) 2010-11-30
NZ584876A (en) 2012-06-29
NI201000069A (es) 2010-08-23
EP2211863A1 (en) 2010-08-04
EP2211863A4 (en) 2012-07-25
GT201000107A (es) 2012-03-13
CA2701956A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
MX361886B (es) Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
NZ594210A (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
MX2008010172A (es) Suministro pulmonar de inhibidor de proteinasa alafa-i.
WO2005102431A3 (en) Aerosol delivery apparatus for pressure assisted breathing
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
MX2010004529A (es) Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
WO2007099329A3 (en) Nebulizer formulation
MX357556B (es) Composiciones acuosas que comprenden arbekacina.
MXPA05008407A (es) Tratamiento de enfermedades bacterianas de los organos respiratorios aplicando localmente fluoroquinolonas.
MY179794A (en) Compound composition for inhalation used for treating asthma
IL168308A (en) Compositions containing roflumilast and formoterol
WO2010048384A3 (en) Arformoterol and tiotropium compositions and methods for use
MX2010002633A (es) Composiciones para inahalacion de dheas.
HK1212902A1 (zh) 诸如nps89636的钙/阳离子感应受体(casr)拮抗剂在治疗炎性肺病(哮喘或copd)中的应用
GB0402679D0 (en) Organic compounds
WO2003094968A3 (en) Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
MX2013004575A (es) Disacaridos hipersulfatados para tratar trastornos relacionados con la elastasa.
HK40086548A (en) Use of agents for treatment of respiratory conditions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal